Ratio of the administered to the scheduled dose of IFN-α and arabinosyl cytosine in the first 2 years of study
| . | IFN-α . | IFN-α + LDAC . | |
|---|---|---|---|
| IFN-α . | LDAC . | ||
| First quarter | 0.72:1 | 0.74:1 | 0.82:1 |
| Second quarter | 0.82:1 | 0.78:1 | 0.63:1 |
| Second half-year | 0.74:1 | 0.72:1 | 0.49:1 |
| Second year | 0.66:1 | 0.68:1 | 0.26:1 |
| . | IFN-α . | IFN-α + LDAC . | |
|---|---|---|---|
| IFN-α . | LDAC . | ||
| First quarter | 0.72:1 | 0.74:1 | 0.82:1 |
| Second quarter | 0.82:1 | 0.78:1 | 0.63:1 |
| Second half-year | 0.74:1 | 0.72:1 | 0.49:1 |
| Second year | 0.66:1 | 0.68:1 | 0.26:1 |
The ratios were done on the basis of the patients who remained in study during each period. For IFN-α, the ratio basically reflects the average reduction of the dose, because almost all the patients continued to receive IFN-α. For arabinosyl cytosine, the ratio reflects more the number of the patients who skipped LDAC completely (the frequency of these cases was 5% during the first quarter, 21% during the second quarter, 31% during the second half-year, and 40% in the second year). In the patients who received arabinosyl cytosine, the administered dose ranged from 0.75 to 0.82 of the scheduled dose.
Abbreviations are explained in Table 1.